We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sandoz Wants Third Court to Rule Novo’s Prandin Patent Invalid
Sandoz Wants Third Court to Rule Novo’s Prandin Patent Invalid
August 30, 2011
Sandoz is the latest generic-drug maker to take a swipe at invalidating a Novo Nordisk patent for diabetes drug Prandin while a high-profile case on the drug is pending before the U.S. Supreme Court.